Kenya Medical Device Vigilance and Adverse Event Reporting under PPB Article 7

Content verification date: October 30, 2026

1. Key takeaways

• Kenya consolidates post-market obligations for medical devices in the Guidelines on Submission of Documentation for Registration of Medical Devices, Article 7, titled Post-Market Requirements and Vigilance System. Its stated purpose is reducing recurrence of serious adverse events; it requires close cooperation among the Pharmacy and Poisons Board (PPB), manufacturers and licensed medical practitioners.
• Under Article 7, manufacturers and the Local Authorized Representative (LAR) must perform six obligations. The first three are record-keeping duties: maintain distribution records for device accountability and traceability (including exports from Kenya); maintain complaint handling procedures and records (including consumer complaints and corrective actions); and maintain adverse event reporting procedures and records. The fourth is an action duty: establish a Field Safety Corrective Action (FSCA) procedure.
• The reporting trigger is outcome-based: wherever device malfunction, deterioration in effectiveness, or inadequacy of labelling and instructions for use causes or may cause death or serious health deterioration of a patient, user or other person, PPB must be notified. Since inadequate labelling sits alongside malfunction as a cause of harm, IFU deficiencies also go through the event reporting channel.
• The receiving end exists: the PPB organisational structure states that the National Pharmacovigilance Center monitors marketed health products and technologies through active and passive surveillance, has a system for receiving reports on device use safety and device-related events, and keeps procedures for receiving, investigating and reviewing field safety action reports.
• Post-market data also flows back into renewal: Rule 9(3)(f) of the 2022 Registration Rules (Legal Notice No. 100 of 2022) requires vigilance and product safety reports in the renewal dossier, covering product complaints and market surveillance. Vigilance is not isolated; it is the starting point of the evidence chain for five-year renewal.

2. Legal basis

3. Expert insights

Insight 1: the six Article 7 obligations are auditable duties, not statements of principle

The GRZAN view is that the decisive difference between Article 7 and vigilance provisions elsewhere is that it anchors every duty to a documentary record. The text does not demand an abstract vigilance system; it demands distribution records, complaint handling procedures and records, adverse event reporting procedures and records, and an FSCA procedure. Each item corresponds to a document PPB can pull during an inspection: establishment inspections, the LAR annual file review and renewal dossiers are all retrieval scenarios. Holding only a group-level SOP without Kenya-specific distribution and complaint ledgers is compliance in form, failure in substance.

Insight 2: the trigger makes inadequate labelling and instructions a cause of harm

The wording of the third Article 7 duty is that notification to PPB is required where device malfunction, deterioration in effectiveness or inadequacy of labelling and instructions for use causes or may cause death or a serious deterioration in health. GRZAN notes that this places three harm pathways side by side: device failure, deteriorating effectiveness, and information defects, meaning labels and IFUs that do not support safe use. The third is most often missed, because mistranslated instructions and missing warnings are treated internally as document issues, yet under the Kenya framework they may be reportable events. Label and IFU revisions are also review-type changes requiring prior approval, so the two workflows must be linked.

Insight 3: SADE sits in the exemption list, a rarely used disposal channel

Section 2.14 of the guidelines lists exemption types including Serious Adverse Device Events (SADE) and export or disposal of devices after a clinical or pharmaceutical study ends. GRZAN reads this as a channel for after-the-fact disposal: when a marketed device must be withdrawn or destroyed after a serious adverse event, a notification with supporting documents is filed with PPB in advance, and PPB issues a payment notice under import and export control requirements on receipt. Those exempted are also exempt from the establishment licence, but not from notification. Obtain the exemption receipt before arranging logistics, so the disposal itself is not treated as unlicensed importation or distribution.

Insight 4: two hard outlets where vigilance data flows back

Post-market data in Kenya has two hard outlets. The first is renewal: Rule 9(3)(f) lists the vigilance and product safety report as a renewal dossier component, and a missing item renders the dossier incomplete. The second is the initial submission: the CSDT must contain sales, complaint and vigilance data for the past 5 years. GRZAN recommends building the data set around four elements, product, batch, event and disposition, retained on a rolling basis.

4. Practical recommendations

1. Fix vigilance clauses in the LAR contract. GRZAN recommends signing a separate vigilance and FSCA delegation agreement alongside the authorisation letter, defining notification deadlines, document formats and contacts for reporting adverse events to PPB, so accountability does not float after an incident.
2. Keep three separate ledgers. Maintain distribution records (including exports from Kenya), complaint handling records and adverse event records as three distinct books, archived by calendar year for instant retrieval at inspection.
3. Add labelling defects to the event triage list. In the internal SOP event assessment sheet, list inadequacy of labelling and instructions for use as a separate column, preventing instruction-type issues from being downgraded internally.
4. Route disposal through the exemption notification first. Where devices must be returned, exported or destroyed because of a SADE, submit the notification and supporting documents to PPB under Section 2.14, obtain the receipt, then execute the logistics.
5. Draft the vigilance and product safety report annually in advance. Produce a draft each year and archive it alongside the annual retention filing so it can be cited directly at renewal.

5. Verification checklist

• □ Has the LAR confirmed in writing that it assumes the six Article 7 obligations, with deadlines and formats agreed?
• □ Do the distribution records cover flows exported from Kenya and allow device-level traceability?
• □ Are complaint handling procedures and records documented, closing the loop on consumer complaints and corrective actions?
• □ Does the adverse event assessment sheet separately list the three trigger pathways: malfunction, deteriorating effectiveness, and inadequate labelling and instructions for use?
• □ Has the intake channel, format and receipt form for reporting to the National Pharmacovigilance Center been confirmed, with one test submission completed?
• □ Can the sales, complaint and vigilance data for the past 5 years in the CSDT be produced immediately?
• □ Has the Section 2.14 exemption notification for export or destruction of affected devices been submitted, with the receipt obtained?
• □ Are annual draft vigilance and product safety reports archived with the annual retention filings?

Regulatory information verified as of October 30, 2026.

In African markets, the GRZAN regulatory team focuses on Kenya, Nigeria, South Africa and Egypt and verifies every published regulatory conclusion against official gazettes, competent authority guidelines and public legal databases, with the verification date marked; figures, cycles and amounts not locatable in official sources are marked as practical estimates, not presumed.

GRZAN services cover market access strategy and risk classification; preparation and review of dossiers in CSDT, STED and CTD formats; selection and management of Local Authorized Representatives (LAR); QMS and GMP/GSDP compliance support; post-market vigilance, change management and recall response; import clearance and PVoC coordination; regulatory intelligence subscriptions and compliance ledgers.

For Kenya post-market compliance support covering vigilance, recalls and inspection readiness, contact the GRZAN regulatory team at info@grzanglobal.com.